Boqii Holding Limited reported fiscal 2026 first half unaudited financial results with total revenues of RMB207.9 million and a 75.1% decrease in net loss to RMB7.4 million. The filing also discloses the disposal of Nanjing Xingmu Biotechnology Co., Ltd. and a subsequent equity repurchase agreement for RMB12.5 million.
Key takeaways
Total revenues for the six months ended September 30, 2025 were RMB207.9 million (US$29.2 million), a decrease from RMB249.7 million in the prior year period.
Net loss narrowed by 75.1% to RMB7.4 million (US$1.0 million), compared to RMB29.6 million in the first half of fiscal 2025.
Gross margin increased to 25.9%, up 520 basis points from 20.7% in the first half of fiscal 2025.
The Company disposed of Nanjing Xingmu Biotechnology Co., Ltd. effective April 1, 2025, and recognized a disposal consideration receivable of RMB41.9 million.
On December 4, 2025, the Company entered into a repurchase agreement to sell its 14.5% equity interest in Nanjing Xingmu for RMB12.5 million in cash.
Total cash and cash equivalents and short-term investments were RMB30.5 million as of September 30, 2025.